Name: Resources
Keywords: Resources

Spevigo (spesolimab) has a conditional marketing authorisation for the treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy

▼This medicinal product is subject to additional monitoring. * Additional efficacy and safety data are being collected.

Click here for prescribing information.

Resources for you

Download

Download

View

GPP Medical Education website

This website is for UK Healthcare Professionals. Patients should be directed to the GPP HUB patient website and not the UK Healthcare Professional site

View

Watch now

Additional important information can be found here, including prescribing information

Quick links

Resources for your patients

Download

View

GPP HUB

Patients should be directed to the GPP HUB patient website and not the UK Healthcare Professional site

View

Learn more

Learn more

PC-GB-109369 V2 | March 2025

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.

Resources

Resources for you

SPEVIGO®▼ (spesolimab) booklet